RxDoctor Payments Data

Donald Neal, DO

Interventional Cardiology · Statesville, NCNPI 1558561670

Payments from drug & device makers

$5,000in general payments, 2019–2025

Across 238 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$552
  • Novartis$385
  • Shockwave Medical, Inc$341
  • Amgen$318
  • Merck$274
  • Boston Scientific$236
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$5,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,000 in reported general payments places this provider in the 35th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$205,102
Medicare patients
940
Services billed
3,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$318,447
OzempicSemaglutide61$72,639
EntrestoSacubitril/Valsartan69$53,621
XareltoRivaroxaban52$42,713
Repatha SureclickEvolocumab59$39,888
FarxigaDapagliflozin Propanediol36$30,736
JardianceEmpagliflozin24$24,069
BrilintaTicagrelor19$14,362
Repatha SyringeEvolocumab12$6,603
Flecainide Acetate93$3,015
Metoprolol Succinate208$1,814
Atorvastatin Calcium161$1,407
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$1,339
ClopidogrelClopidogrel Bisulfate95$870
Rosuvastatin Calcium137$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$318,447353 claims
Novo NordiskOzempic$117$72,63961 claims
NovartisEntresto$385$53,62169 claims
AstraZenecaFarxiga, Brilinta$131$45,09755 claims
Johnson & JohnsonXarelto$552$42,71352 claims
Boehringer IngelheimJardiance$235$24,06924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →